过去一年中添加的文章，按日期排序
[HTML][HTML] Innovative Drug Discovery Research by Pharmaceutical Companies in India and China
S Kumar - Journal of Medicinal Chemistry, 2024 - ACS Publications
21 天前 - … in the UK, and 80% of the global supply of antiviral drugs for AIDS. (1) India has …
drugs during this period received US FDA approval. Of these six drugs, the first approval was …
drugs during this period received US FDA approval. Of these six drugs, the first approval was …
POS1476-HPR THE ADJUVANTED RECOMBINANT ZOSTER VACCINE IS EFFECTIVE IN PATIENTS≥ 50 YEARS OF AGE WITH RHEUMATOID ARTHRITIS AT …
D Constenla, G Lonnet, E Aris, H Wang, R Rk… - 2024 - ard.bmj.com
30 天前 - … is approved for use in HZ prevention by the US Food and … The first HZ event during
follow-up was identified using an … HZ antiviral medication used within 7 days before/after HZ …
follow-up was identified using an … HZ antiviral medication used within 7 days before/after HZ …
Disparities in access to Dolutegravir in West African children, adolescents and young adults aged 0-24 years living with HIV. A IeDEA Pediatric West African cohort …
S Desmonde, J Dame, K Malateste, A David… - medRxiv, 2024 - medrxiv.org
37 天前 - … NOTE: This preprint reports new research that has not been certified by peer review
and … between children and adolescents living with HIV with HIV drug-resistance and those …
and … between children and adolescents living with HIV with HIV drug-resistance and those …
Switch to fixed-dose doravirine (100 mg) with islatravir (0· 75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a …
JM Molina, G Rizzardini, C Orrell, A Afani, A Calmy… - … Lancet HIV, 2024 - thelancet.com
53 天前 - … continued to take the medication according to the locally approved label. HIV-1
RNA … The primary endpoint was proportion of participants with greater than or equal to 50 HIV…
RNA … The primary endpoint was proportion of participants with greater than or equal to 50 HIV…
[HTML][HTML] User Experience of Persons Using Ingestible Sensor–Enabled Pre-Exposure Prophylaxis to Prevent HIV Infection: Cross-Sectional Survey Study
S Browne, A Umlauf, DJ Moore… - JMIR mHealth and …, 2024 - mhealth.jmir.org
59 天前 - … the Food and Drug Administration–approved Digital Health Feedback … medication
adherence, after they were prescribed oral pre-exposure prophylaxis (PrEP) to prevent HIV …
adherence, after they were prescribed oral pre-exposure prophylaxis (PrEP) to prevent HIV …
[HTML][HTML] Delphi Method Analysis and Consensus of Prevalent Distinctive Practices for Biliary Atresia Management after Kasai Portoenterostomy
S Vutukuru, S Solanki, RP Kanojia - Journal of Indian Association …, 2024 - journals.lww.com
61 天前 - … antiviral drugs to children who are cytomegalovirus immunoglobulin M positive. In
our survey, 50% of experts perform 5–10 KPE per year, … [ 23 , 24 ] This has been accepted by …
our survey, 50% of experts perform 5–10 KPE per year, … [ 23 , 24 ] This has been accepted by …
[引用][C] Another link between adult orbital xanthogranulomatous disease and IgG4-related disease
T Carpenter, C Ye, A Wolff, E Capitle - Annals of Allergy, Asthma & …, 2024 - annallergy.org
73 天前 - … Diagnostic criteria for IgG4-RD remain controversial and have not been approved
by the American College of Rheumatology because they are not sufficiently sensitive or …
by the American College of Rheumatology because they are not sufficiently sensitive or …
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care
G Pierone Jr, L Brunet, JS Fusco… - HIV/AIDS-Research …, 2024 - Taylor & Francis
76 天前 - … was approved in the US for both treatment-naïve and treatment-experienced
individuals with a viral load <50 … DTG/3TC 2DR treatment outcomes among treatment-experienced …
individuals with a viral load <50 … DTG/3TC 2DR treatment outcomes among treatment-experienced …
[HTML][HTML] Two-drug regimens dolutegravir/lamivudine and dolutegravir/rilpivirine are effective with few discontinuations in US real-world settings: results from the …
S Schneider, G Blick, C Burke, D Ward… - Infectious Diseases and …, 2024 - Springer
89 天前 - … , was approved by the FDA in 2019 for the treatment of ART… are virologically
suppressed (HIV-1 RNA < 50 copies/mL) … of all HIV treatment centers across the USA. Additionally, …
suppressed (HIV-1 RNA < 50 copies/mL) … of all HIV treatment centers across the USA. Additionally, …
[HTML][HTML] Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study …
P Benson, J Kuretski, C Donovan, G Harper… - Infectious Diseases and …, 2024 - Springer
89 天前 - … inhibitor-based, 2-drug regimens (2DRs) approved for treatment of people with …
abuse (ie, injection drug use, alcohol abuse), affordability of HIV medications, and difficult work …
abuse (ie, injection drug use, alcohol abuse), affordability of HIV medications, and difficult work …